[8-K] Kiora Pharmaceuticals, Inc. Reports Material Event

Rhea-AI Filing Summary

Kiora Pharmaceuticals, Inc. reported via an 8-K that on August 8, 2025 it issued a press release announcing financial results for the quarter ended June 30, 2025 and provided an update on its clinical development progress. The press release is furnished as Exhibit 99.1 and an Inline XBRL cover page is included as Exhibit 104. The filing states that the furnished information, including Exhibit 99.1, is not deemed "filed" under Section 18 and is not incorporated by reference into other Securities Act or Exchange Act filings except where expressly stated.

The report is signed by Melissa Tosca, Chief Financial Officer. No financial line-item figures or clinical data are presented within the 8-K text itself; readers must refer to Exhibit 99.1 for the detailed press release content.

Insights

Financial Analyst

TL;DR: Routine 8-K furnishing a press release on Q2 2025 results and a clinical update; no financial details are included in the filing itself.

The filing formally notifies investors that Kiora furnished a press release on August 8, 2025 announcing results for the quarter ended June 30, 2025 and clinical development progress. The 8-K supplies exhibit identifiers but contains no financial totals, metrics, or forward-looking statements. The disclosure approach—furnishing versus filing—limits legal incorporation by reference, which is a common procedural choice. For material financial assessment, the attached Exhibit 99.1 must be reviewed.

Clinical Development Specialist

TL;DR: The 8-K notes a clinical development update was announced but provides no trial data or specifics within the filing.

The document confirms Kiora provided a clinical development update as part of the August 8, 2025 press release. No trial names, phase progression, endpoints, enrollment updates, regulatory interactions, or data are included in the 8-K text. As such, the filing signals communication activity but contains no clinical details that would permit technical evaluation of program progress or timelines; the press release (Exhibit 99.1) is the necessary source for substantive clinical information.

0001372514false00013725142025-08-082025-08-08

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

FORM 8-K

CURRENT REPORT PURSUANT

TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported): August 8, 2025

KIORA PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)

Delaware

(State or other jurisdiction of incorporation)

001-36672			98-0443284
(Commission File Number)			(IRS Employer Identification No.)

169 Saxony Rd.

Suite 212

Encinitas, CA 92024

(858) 224-9600

(Registrant’s telephone number, including area code)

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐			Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐			Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐			Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐			Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class:

Trading Symbol(s)

Name of each exchange on which registered:

Common Stock, $0.01 par value

KPRX

NASDAQ

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02.    Results of Operations and Financial Conditions.

On August 8, 2025, Kiora Pharmaceuticals, Inc. (the “Company”) issued a press release announcing financial results for the quarter ended June 30, 2025 and an update on clinical development progress. A copy of the release is attached as Exhibit 99.1.

The information furnished pursuant to this Item 2.02, including Exhibit 99.1, is not deemed to be “filed” for purposes of Section 18 of the Exchange Act, or otherwise subject to the liability of that section. This information will not be deemed to be incorporated by reference into any filing under the Securities Act or the Exchange Act, except to the extent that the registrant specifically incorporates them by reference.

Item 9.01.    Financial Statements and Exhibits.

(d) Exhibits.

Exhibit  Number						Title
99.1						Press Release of Kiora Pharmaceuticals, Inc., dated as of August 8, 2025
104						Cover Page Interactive Data File (embedded within the Inline XBRL document).

*Schedules and exhibits have been omitted pursuant to Item 601(a)(5) of Regulation S-K. The registrant hereby undertakes to furnish copies of any of the omitted schedules and exhibits upon request by the U.S. Securities and Exchange Commission.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

			KIORA PHARMACEUTICALS, INC.
			By:			/s/ Melissa Tosca
						Melissa Tosca
						Chief Financial Officer
						(Principal financial and accounting officer)
			Date: August 8, 2025

FAQ

What did Kiora (KPRX) disclose in the August 8, 2025 8-K?

The 8-K states Kiora issued a press release on August 8, 2025 announcing financial results for the quarter ended June 30, 2025 and providing a clinical development update; the release is furnished as Exhibit 99.1.

Does the 8-K include the financial figures for Q2 2025?

No. The 8-K does not contain specific financial line-item figures; it furnishes a press release with the results as Exhibit 99.1, which must be consulted for the financial details.

Where can I find the press release referenced in the 8-K?

The press release is attached to the filing as Exhibit 99.1; the filing also includes an Inline XBRL cover page as Exhibit 104.

Is the information in the 8-K considered 'filed' under the Exchange Act?

The 8-K expressly states that the information furnished under Item 2.02, including Exhibit 99.1, is not deemed to be filed under Section 18 of the Exchange Act and is not incorporated by reference into other filings unless expressly stated.

Who signed the 8-K for Kiora Pharmaceuticals?

The 8-K is signed by Melissa Tosca, Chief Financial Officer, dated August 8, 2025.